We're building on established biology & investigating complementary mechanisms, both individually & in combination, w/ the goal of developing next-gen therapies for those living w/ chronic inflammatory diseases. More about our approach & opportunities: spyre.com.
1
53
We're developing next-gen therapies w/ the goal of delivering more complete disease control, greater durability & simpler treatment experience for those living w/ chronic inflammatory diseases. See what we think about the future of #immunology treatment @ spyre.com
10
A huge congratulations to Spyre's Olivia Ballew on qualifying for the Olympic Trials in the marathon with a time of 2:36:15!
We're proud to celebrate this incredible achievement and cheer her on as she continues her running journey.
9
Spyre will participate in upcoming investor conferences, including UBS Global Biopharma, #JefferiesHealthcare, Evercore Healthcare, and Citi Global Healthcare.
See below for details and access webcasts: ir.spyre.com/events-and-pres…
ir.spyre.com/news-releases/n…
1
34
Today, we shared Q3 2026 financial results and corporate updates, highlighting clinical progress, upcoming milestones across IBD and HS, and the financial resources to support our development. More & FLS: ir.spyre.com/news-releases/n…
1
24
At #UEGW2026, we're presenting clinical data across SPY001/002/003 and new preclinical findings demonstrating additive efficacy, supporting our approach to investigating combinations in #IBD.
FLS & more: ir.spyre.com/news-releases/n…
68
We recently announced a $350M financing to support the advancement of SPY072 into late-stage development for hidradenitis suppurativa.
This brings Spyre’s total capital raised to more than $2B since inception, with a pro forma cash position of ~$1.5 billion*.
1
40
For #HispanicHeritageMonth, we welcomed Valerie Zolezzi-Wyndham, founder of Promoting Good and Casita Cultura Latina, to share her heritage and lead our team in rounds of Lotería! Thank you to Valerie and our IBC committee for bringing us together to celebrate and connect.
60
Complexity equals possibility.
At Spyre, that complexity is shaping how we think about the next generation of therapies and the potential of addressing multiple pathways simultaneously. Learn more at spyre.com.
31
Meet Laura Kaligaric, Senior Director of Quality Systems & Compliance at Spyre. From creating efficiencies across our organization to collaborating with colleagues, Laura shares what she enjoys about her work, our culture and the mission that brings it all together.
35
We shared positive Phase 2 SKYLINE Part A results for SPY003 in UC:
→ 10.0 point reduction in RHI (p<0.0001)
→ 20% clinical remission
→ 30% endoscopic improvement
These results establish clinical POC across all 3 mechanisms in our #IBD portfolio. FLS: ir.spyre.com/news-releases/n…
65
We’re looking forward to connecting with the investment community at three conferences this September: Citi BioPharma Back to School, Wells Fargo Healthcare and Stifel’s Immunology & Inflammation Forum.
Access the webcasts and learn more: ir.spyre.com/news-releases/n…
🤖 Made with AI
46
Today we announced the launch of our SPY772 program and initiation of the SKYLIGHT Phase 2 clinical trial, which is designed to provide clinical POC for TL1A and IL-17A/F inhibition in #HidradenitisSuppurativa (#HS).
PR and FLS: ir.spyre.com/news-releases/n…
3
111
TL1A plays a key role in activating immune cells & driving persistent inflammation in #IBD. We are investigating SPY002, a novel, half-life extended investigational monoclonal antibody targeting TL1A for potential treatment of IBD. FLS: Spyre.com MoA: @visualscience
1
44
Our Q2 2026 financial results and corporate update are out. SPY001 and SPY002 met primary endpoints in SKYLINE Part A. SKYWAY enrollment complete. 6 Phase 2 readouts on track for 2026. $1.1B cash, runway into H2 2029. More along with our FLS: ir.spyre.com/news-releases/n…
33





































